• TIVDAK (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy | The Manila Times

    来源: Buzz FX / 27 3月 2025 08:26:35   America/New_York


    Media Release
    COPENHAGEN, Denmark; March 27, 2025
    TIVDAK is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in Japan Approval is based on results from the global Phase 3 in
    Read more...
分享